Multiple Myeloma Hub ASH 2025 | CARTITUDE-4: Long-term PFS outcomes with cilta-cel for standard-risk RRMM
Dec 11, 2025
Luciano Costa, a myeloma physician and researcher from the University of Alabama at Birmingham, dives into the fascinating long-term outcomes of the CARTITUDE-4 trial featuring cilta-cel for standard-risk relapsed/refractory multiple myeloma. He highlights how approximately 71% of patients remain progression-free at 30 months and discusses the promising implications for standard-risk patients. Costa also underscores the significant rates of minimal residual disease negativity and speculates that cilta-cel could become a one-time curative option for some, transforming treatment paradigms.
AI Snips
Chapters
Transcript
Episode notes
CARTITUDE‑4 Shows Clear Survival Benefit
- CARTITUDE-4 randomized lenalidomide-refractory patients to standard regimens versus bridging therapy followed by a single infusion of cilta-cel.
- The trial demonstrated clear progression-free and overall survival advantages for cilta-cel versus standard care.
Trial Design Summary From The Investigator
- Luciano Costa described the CARTITUDE‑4 trial design: investigator‑chosen bridging regimen followed by cilta‑cel infusion.
- He emphasized the trial enrolled lenalidomide‑refractory patients with one to three prior lines of therapy.
Don't Reserve Cilta‑cel Only For High Risk
- Avoid reserving cilta‑cel only for high‑risk patients because standard‑risk patients derive substantial benefit.
- Consider earlier use in eligible standard‑risk patients rather than defaulting to later lines.